European guidelines for sclerotherapy in chronic venous disorders

Aim: Sclerotherapy is the targeted chemical ablation of varicose veins by intravenous injection of a liquid or foamed sclerosing drug. The treated veins may be intradermal, subcutaneous, and/or transfascial as well as superficial and deep in venous malformations. The aim of this guideline is to give...

Full description

Bibliographic Details
Main Authors: Rabe, E., Breu, F., Cavezzi, A., Coleridge Smith, P., Frullini, A., Gillet, J., Guex, J., Hamel-Desnos, C., Kern, P., Partsch, B., Ramelet, Anne-Sylvie, Tessari, L., Pannier, F.
Format: Journal Article
Published: 2013
Online Access:http://www.revue-phlebologie.org/donnees/archives/acces_article.php
http://hdl.handle.net/20.500.11937/37250
_version_ 1848754994941001728
author Rabe, E.
Breu, F.
Cavezzi, A.
Coleridge Smith, P.
Frullini, A.
Gillet, J.
Guex, J.
Hamel-Desnos, C.
Kern, P.
Partsch, B.
Ramelet, Anne-Sylvie
Tessari, L.
Pannier, F.
author_facet Rabe, E.
Breu, F.
Cavezzi, A.
Coleridge Smith, P.
Frullini, A.
Gillet, J.
Guex, J.
Hamel-Desnos, C.
Kern, P.
Partsch, B.
Ramelet, Anne-Sylvie
Tessari, L.
Pannier, F.
author_sort Rabe, E.
building Curtin Institutional Repository
collection Online Access
description Aim: Sclerotherapy is the targeted chemical ablation of varicose veins by intravenous injection of a liquid or foamed sclerosing drug. The treated veins may be intradermal, subcutaneous, and/or transfascial as well as superficial and deep in venous malformations. The aim of this guideline is to give evidence-based recommendations for liquid and foam sclerotherapy. Methods: This guideline was drafted on behalf of 23 European Phlebological Societies during a Guideline Conference on 7-10 May 2012 in Mainz. The conference was organized by the German Society of Phlebology. These guidelines review the present state of knowledge as reflected in published medical literature. The regulatory situation of sclerosant drugs differs from country to country but this has not been considered in this document. The recommendations of this guideline are graded according to the American College of Chest Physicians Task Force recommendations on Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines. Results: This guideline focuses on the two sclerosing drugs which are licensed in the majority of the European countries, polidocanol and sodium tetradecyl sulphate. Other sclerosants are not discussed in detail. The guideline gives recommendations concerning indications, contraindications, side-effects, concentrations, volumes, technique and efficacy of liquid and foam sclerotherapy of varicose veins and venous malformations.
first_indexed 2025-11-14T08:49:15Z
format Journal Article
id curtin-20.500.11937-37250
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:49:15Z
publishDate 2013
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-372502017-01-30T14:01:03Z European guidelines for sclerotherapy in chronic venous disorders Rabe, E. Breu, F. Cavezzi, A. Coleridge Smith, P. Frullini, A. Gillet, J. Guex, J. Hamel-Desnos, C. Kern, P. Partsch, B. Ramelet, Anne-Sylvie Tessari, L. Pannier, F. Aim: Sclerotherapy is the targeted chemical ablation of varicose veins by intravenous injection of a liquid or foamed sclerosing drug. The treated veins may be intradermal, subcutaneous, and/or transfascial as well as superficial and deep in venous malformations. The aim of this guideline is to give evidence-based recommendations for liquid and foam sclerotherapy. Methods: This guideline was drafted on behalf of 23 European Phlebological Societies during a Guideline Conference on 7-10 May 2012 in Mainz. The conference was organized by the German Society of Phlebology. These guidelines review the present state of knowledge as reflected in published medical literature. The regulatory situation of sclerosant drugs differs from country to country but this has not been considered in this document. The recommendations of this guideline are graded according to the American College of Chest Physicians Task Force recommendations on Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines. Results: This guideline focuses on the two sclerosing drugs which are licensed in the majority of the European countries, polidocanol and sodium tetradecyl sulphate. Other sclerosants are not discussed in detail. The guideline gives recommendations concerning indications, contraindications, side-effects, concentrations, volumes, technique and efficacy of liquid and foam sclerotherapy of varicose veins and venous malformations. 2013 Journal Article http://hdl.handle.net/20.500.11937/37250 http://www.revue-phlebologie.org/donnees/archives/acces_article.php restricted
spellingShingle Rabe, E.
Breu, F.
Cavezzi, A.
Coleridge Smith, P.
Frullini, A.
Gillet, J.
Guex, J.
Hamel-Desnos, C.
Kern, P.
Partsch, B.
Ramelet, Anne-Sylvie
Tessari, L.
Pannier, F.
European guidelines for sclerotherapy in chronic venous disorders
title European guidelines for sclerotherapy in chronic venous disorders
title_full European guidelines for sclerotherapy in chronic venous disorders
title_fullStr European guidelines for sclerotherapy in chronic venous disorders
title_full_unstemmed European guidelines for sclerotherapy in chronic venous disorders
title_short European guidelines for sclerotherapy in chronic venous disorders
title_sort european guidelines for sclerotherapy in chronic venous disorders
url http://www.revue-phlebologie.org/donnees/archives/acces_article.php
http://hdl.handle.net/20.500.11937/37250